**Discovery Partnerships with Academia: Project Form**

GSK’s Discovery Partnerships with Academia aims to translate innovative academic research into medicines of value by establishing project-based collaborations that operate in a unique, interactive and integrated fashion. We are searching for partners who have a novel therapeutic idea that has the potential to transform the lives of patients. Since we are looking specifically for drug discovery projects, ideas for a new technology, vaccine, biomarker or device are not in scope for DPAc. To help us evaluate your proposal please provide concise answers to the questions below, including key data and references. Please provide only **non-confidential** material at this stage. We will provide feedback on all proposals we receive and will contact you if we require further information.

|  |  |  |  |
| --- | --- | --- | --- |
| **Institute** |  | **City/Country** |  |
| **Principal Investigators** |  | **Department/School** |  |
| **Project Title** |  | **Date** |  |

|  |
| --- |
| **What is the therapeutic hypothesis?** For example: Describe the biological rationale that supports the hypothesis that modulation of the target will bring benefit to patients. Describe the disease and unmet medical need, how the disease manifests and how patients are currently managed. |
|  |
| **What is the specific target or pathway?**For example: Describe the protein/gene/pathway you would like to target. Where is the target expressed and what is its role in normal physiology? What differentiates this target from other approaches in this disease?  |
|  |
| **What is the current project status and enabling expertise to support the project?**For example: Describe the work which has been undertaken in your laboratory to further characterise the target. Highlight any specific expertise, resources or capabilities in your laboratory or institution that are not readily found elsewhere. |
|  |
| **What is the tractability of the proposition?**For example: Where is the target located and what is its molecular function? How do you want to modulate the target? What modality (e.g. small molecule, monoclonal antibody) do you propose to utilise? What could we measure in patients to show that the therapeutic is working? How long might it be necessary to treat patients to see this effect?  |
|  |
| **What is the requirement for the GSK contribution**What expertise do you believe that GSK could bring to this project to complement your existing capabilities?  |
|  |